Amneal Pharmaceuticals (NYSE:AMRX) Price Target Raised to $5

Amneal Pharmaceuticals (NYSE:AMRX – Free Report) had its price objective upped by Piper Sandler from $3.00 to $5.00 in a report published on Monday morning, Marketbeat.com reports. They currently have an overweight rating on the stock. Other equities analysts have also recently issued reports about the company. 500.com reissued a maintains rating on shares of […]

Related Keywords

Switzerland , Swiss , Piper Sandler , Metlife Investment Management , Swiss National Bank , News Ratings For Amneal Pharmaceuticals Daily , York Mellon Corp , Barclays , Blackrock Inc , Amneal Pharmaceuticals Price Performance , Amneal Pharmaceuticals , Amneal Pharmaceuticals Company Profile , Panagora Asset Management Inc , Amneal Pharmaceuticals Inc , Analyst Recommendations For Amneal Pharmaceuticals , Free Report , Moderate Buy , National Bank , New York Mellon Corp , Life Investment Management , Asset Management , Get Free Report , Amneal Pharmaceuticals Daily , Nyse Amrx , Amrx , Medical , Boost Price Target ,